Optic Neuropathy Clinical Trial
Official title:
Evaluation of the Effect of Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy
Verified date | March 2021 |
Source | Alexandria University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 30, 2020 |
Est. primary completion date | December 15, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases) Exclusion Criteria: - Patients with perforating ocular injuries were excluded. |
Country | Name | City | State |
---|---|---|---|
Egypt | Alexandria Faculty of Medicine | Alexandria |
Lead Sponsor | Collaborator |
---|---|
Alexandria University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of visual acuity | Visual acuity using appropriate charts for assessment then convert into log of the minimum angle of resolution (logMAR) units to provide a numeric scale of visual acuity | 3 months | |
Primary | Flash visual-evoked potentials | Flash VEP to detect amplitude reduction and latency in the optic nerve. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02982499 -
Biomechanics of Optic Neuropathy
|
||
Recruiting |
NCT05543018 -
Effect of Intraocular Tamponade on Visual Perception
|
N/A | |
Completed |
NCT03318549 -
BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases
|
N/A | |
Terminated |
NCT03536559 -
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT06128720 -
Hyperbaric Oxygen Therapy for Optic Neuropathies
|
N/A | |
Withdrawn |
NCT01331616 -
Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab
|
Early Phase 1 | |
Not yet recruiting |
NCT05747781 -
STReetlab Assessment Tool of Activities Daily Living in Glaucoma Patient
|
N/A | |
Completed |
NCT01166594 -
Use of Bevacizumab in Trabeculectomy Surgery
|
Phase 4 | |
Completed |
NCT03268681 -
BIOtinidase Test In Optic-Neuropathy
|
||
Completed |
NCT02612571 -
Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players
|
N/A | |
Recruiting |
NCT03011541 -
Stem Cell Ophthalmology Treatment Study II
|
N/A | |
Completed |
NCT05853003 -
Neuromuscular Ultrasonography Assessment of Optic Nerve in Systemic Lupus Eryhematosus
|
||
Enrolling by invitation |
NCT03760055 -
Assessment of Visual Function With a Portable Brain-computer Interface
|
||
Recruiting |
NCT02638714 -
Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells
|
Phase 1/Phase 2 |